Comment | Published:

Clinical tumour sequencing for precision oncology: time for a universal strategy

Nature Reviews Cancervolume 18pages527528 (2018) | Download Citation

Routine, comprehensive molecular characterization of patient tumours has the potential to accelerate therapeutic advances and inform cancer biology. Here, we describe insights from the implementation of an enterprise-wide, prospective clinical sequencing strategy at an academic cancer centre.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

  2. 2.

    Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).

  3. 3.

    Mandelker, D. et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA versus guideline-based germline testing. JAMA 318, 825–835 (2017).

  4. 4.

    Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

  5. 5.

    Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).

  6. 6.

    Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251–2259 (2017).

  7. 7.

    Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189–194 (2018).

  8. 8.

    Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374–382 (2017).

Download references

Author information

Affiliations

  1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Michael L. Cheng
    • , David M. Hyman
    •  & David B. Solit
  2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Michael F. Berger
  3. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Michael F. Berger
    •  & David B. Solit

Authors

  1. Search for Michael L. Cheng in:

  2. Search for Michael F. Berger in:

  3. Search for David M. Hyman in:

  4. Search for David B. Solit in:

Competing interests

D.B.S. has served in a consulting or advisory role to Loxo Oncology and Pfizer. D.M.H. has served in a consulting or advisory role to Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer and Genentech, and received research funding from AstraZeneca, Puma Biotechnology and Loxo Oncology. M.L.C. and M.F.B. declare no competing interests.

Corresponding author

Correspondence to David B. Solit.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41568-018-0043-2

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing